Standout Papers
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study (2016)
- Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study (2017)
- A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis (2023)
Immediate Impact
2 from Science/Nature 102 standout
Citing Papers
Therapeutic advances in rheumatoid arthritis
2024 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Works of Edit Drescher being referenced
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
2016 Standout
LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Edit Drescher | 892 | 454 | 471 | 35 | 1.3k | |
| Šárka Forejtová | 1001 | 401 | 399 | 32 | 1.4k | |
| Yihan Li | 922 | 525 | 385 | 33 | 1.2k | |
| Li Xie | 723 | 377 | 313 | 22 | 1.3k | |
| Chuanbo Zang | 582 | 296 | 379 | 40 | 1.2k | |
| Jacques‐Eric Gottenberg | 928 | 311 | 318 | 58 | 1.4k | |
| Birgitta Benda | 1177 | 654 | 407 | 21 | 1.7k | |
| Jose L. Rivas | 805 | 298 | 284 | 26 | 1.3k | |
| Stephen Kelly | 784 | 226 | 546 | 39 | 1.4k | |
| Shihong Sheng | 721 | 645 | 741 | 27 | 1.4k | |
| Marijn Vis | 962 | 329 | 477 | 67 | 1.4k |
All Works
Loading papers...